Etelcalcetide for the treatment of secondary hyperparathyroidism.
about
A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.
P2860
Etelcalcetide for the treatment of secondary hyperparathyroidism.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@en
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@nl
type
label
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@en
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@nl
prefLabel
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@en
Etelcalcetide for the treatment of secondary hyperparathyroidism.
@nl
P2860
P1476
Etelcalcetide for the treatment of secondary hyperparathyroidism
@en
P2093
Naoto Hamano
P2860
P304
P356
10.1080/14656566.2017.1303482
P407
P577
2017-03-15T00:00:00Z